Recurrent squamous-cell carcinoma of the head and neck: overview of current therapy and future prospects.
Locoregional recurrence is the most common cause of failure after head and neck cancer surgery. It is a disease which causes significant morbidity especially on speech and swallowing. There are many different treatments available including surgery, reirradiation and chemotherapy. However, none of these have produced any significant survival benefit. Because of this, there has been considerable interest in the development of new biological therapies such as gene therapy and immunotherapy for this disease. The objectives of this article are to provide an overview of the currently available therapies for recurrent head and neck cancer including gene therapy and immunotherapy. Prevention of recurrent disease by the detection and treatment of minimal residual disease is also discussed.
Ganly
I
I
Department of Otolaryngology, Victoria Infirmary, Glasgow, UK. ig8j@udcf.gla.ac.uk
Kaye
S B
SB
D002294:Carcinoma, Squamous Cell / Q000628:therapy*; D015316:Genetic Therapy; D006258:Head and Neck Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control / Q000628:therapy*